Abiraterona en cáncer de próstata hormono-sensible metastásico

5 / 32

LATITUDE: primary efficacy endpoints, OS
Addition of AA+P to ADT significantly improved OS, with a
38% reduction in the risk of death
Fizazi K et al. N Engl J Med 2017;377(4):352-360
LATITUDE: primary efficacy endpoints, OS
Addition of AA+P to ADT significantly improved OS, with a
38% reduction in the risk of death
Fizazi K et al. N Engl J Med 2017;377(4):352